3 October 2018 - Xeljanz has been recommended by NICE for adults with psoriatic arthritis.

Tofacitinib is recommended as an option for treating active psoriatic arthritis in adults, only if:

• it is used as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or
  
• the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or
  
• TNF‑alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
  

Tofacitinib is only recommended if the company provides it according to the commercial arrangement.

Read NICE recommendation